686 related articles for article (PubMed ID: 19726457)
1. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy.
Gridelli C; Rossi A; Maione P; Ferrara ML; Castaldo V; Sacco PC
Oncologist; 2009 Sep; 14(9):909-20. PubMed ID: 19726457
[TBL] [Abstract][Full Text] [Related]
2. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience.
Mellstedt H; Vansteenkiste J; Thatcher N
Lung Cancer; 2011 Jul; 73(1):11-7. PubMed ID: 21474197
[TBL] [Abstract][Full Text] [Related]
3. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.
De Pas T; Giovannini M; Rescigno M; Catania C; Toffalorio F; Spitaleri G; Delmonte A; Barberis M; Spaggiari L; Solli P; Veronesi G; De Braud F
Crit Rev Oncol Hematol; 2012 Sep; 83(3):432-43. PubMed ID: 22366114
[TBL] [Abstract][Full Text] [Related]
4. Active immunotherapy for non-small-cell lung cancer: moving toward a reality.
Perez CA; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1599-605. PubMed ID: 21999133
[TBL] [Abstract][Full Text] [Related]
5. Is vaccine therapy a renewed strategic approach for non-small-cell lung cancer therapy?
Rossi A
Expert Rev Vaccines; 2013 Jan; 12(1):5-7. PubMed ID: 23256734
[No Abstract] [Full Text] [Related]
6. Non-small-cell lung cancer vaccine therapy: a concise review.
O'Mahony D; Kummar S; Gutierrez ME
J Clin Oncol; 2005 Dec; 23(35):9022-8. PubMed ID: 16219932
[TBL] [Abstract][Full Text] [Related]
7. The role of targeted therapy in non-small cell lung cancer.
Maione P; Rossi A; Airoma G; Ferrara C; Castaldo V; Gridelli C
Crit Rev Oncol Hematol; 2004 Jul; 51(1):29-44. PubMed ID: 15207252
[TBL] [Abstract][Full Text] [Related]
8. Autologous dendritic cell vaccines for non-small-cell lung cancer.
Hirschowitz EA; Foody T; Kryscio R; Dickson L; Sturgill J; Yannelli J
J Clin Oncol; 2004 Jul; 22(14):2808-15. PubMed ID: 15254048
[TBL] [Abstract][Full Text] [Related]
9. Novel targeted agents for lung cancer.
West HJ
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S41-6. PubMed ID: 19362946
[TBL] [Abstract][Full Text] [Related]
10. Future directions in the treatment of non-small cell lung cancer.
Shepherd FA
Semin Oncol; 1994 Jun; 21(3 Suppl 4):48-62. PubMed ID: 8209277
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
Grossi F; Tiseo M
Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
Nemunaitis J; Dillman RO; Schwarzenberger PO; Senzer N; Cunningham C; Cutler J; Tong A; Kumar P; Pappen B; Hamilton C; DeVol E; Maples PB; Liu L; Chamberlin T; Shawler DL; Fakhrai H
J Clin Oncol; 2006 Oct; 24(29):4721-30. PubMed ID: 16966690
[TBL] [Abstract][Full Text] [Related]
13. Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines.
Raez LE; Santos ES; Mudad R; Podack ER
Expert Rev Anticancer Ther; 2005 Aug; 5(4):635-44. PubMed ID: 16111464
[TBL] [Abstract][Full Text] [Related]
14. L-BLP25: a peptide vaccine strategy in non small cell lung cancer.
Sangha R; Butts C
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4652-4. PubMed ID: 17671159
[TBL] [Abstract][Full Text] [Related]
15. Non-small-cell lung carcinoma vaccines in clinical trials.
Rossi A; Maione P; Schettino C; Bareschino MA; Sacco PC; Ambrosio R; Barbato V; Zeppa R; Palazzolo G; Gridelli C
Expert Rev Vaccines; 2011 Jun; 10(6):887-97. PubMed ID: 21692707
[TBL] [Abstract][Full Text] [Related]
16. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.
Tyagi P; Mirakhur B
Clin Lung Cancer; 2009 Sep; 10(5):371-4. PubMed ID: 19808198
[TBL] [Abstract][Full Text] [Related]
17. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
Reck M
Ann Oncol; 2012 Sep; 23 Suppl 8():viii28-34. PubMed ID: 22918925
[TBL] [Abstract][Full Text] [Related]
18. MAGE A3 antigen-specific cancer immunotherapeutic.
Peled N; Oton AB; Hirsch FR; Bunn P
Immunotherapy; 2009 Jan; 1(1):19-25. PubMed ID: 20635969
[TBL] [Abstract][Full Text] [Related]
19. Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments.
van Meerbeeck JP; Surmont VF
Lung Cancer; 2009 Sep; 65(3):257-67. PubMed ID: 19285751
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for lung cancer.
Bradbury PA; Shepherd FA
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S164-70. PubMed ID: 18520304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
